Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 419853, 11 pages
http://dx.doi.org/10.1155/2014/419853
Research Article

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies

1Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, F46, Huddinge University Hospital, 141 86 Stockholm, Sweden
2Division of Cognitive Neurophysiology and Osher Center for Integrative Medicine, Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
3Stress Research Center, Stockholm University, 106 91 Stockholm, Sweden
4Department of Chest Diseases, Eskisehir Osmangazi University Medical Faculty, 260 40 Eskisehir, Turkey

Received 9 May 2014; Accepted 30 June 2014; Published 24 July 2014

Academic Editor: Dragana Nikitovic

Copyright © 2014 Filip Mundt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Mortensen, R. Bhatnagar, and A. J. Edey, “Imaging the pleura,” British Journal of Hospital Medicine, vol. 73, no. 11, pp. 626–632, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Kassis, J. Klominek, and E. C. Kohn, “Tumor microenvironment: what can effusions teach us?” Diagnostic Cytopathology, vol. 33, no. 5, pp. 316–319, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Bielsa, A. Salud, M. Martínez et al., “Prognostic significance of pleural fluid data in patients with malignant effusion,” European Journal of Internal Medicine, vol. 19, no. 5, pp. 334–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. I. S. Fentiman, R. Millis, S. Sexton, and J. L. Hayward, “Pleural effusion in breast cancer: a review of 105 cases,” Cancer, vol. 47, no. 8, pp. 2087–2092, 1981. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Nasser and T. J. Kuntzman, “Pleural effusion in women with a known adenocarcinoma: the role of immunostains in uncovering another hidden primary tumor,” Acta Cytologica, vol. 55, no. 5, pp. 438–444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Lombardi, F. Zustovich, M. O. Nicoletto, M. Donach, G. Artioli, and D. Pastorelli, “Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 33, no. 4, pp. 420–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Usami, S. Iwano, and K. Yokoi, “Solitary fibrous tumor of the pleura: evaluation of the origin with 3D CT angiography,” Journal of Thoracic Oncology, vol. 2, no. 12, pp. 1124–1125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. V. B. Antony, R. Loddenkemper, P. Astoul et al., “Management of malignant pleural effusions,” European Respiratory Journal, vol. 18, no. 2, pp. 402–419, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Loddenkemper, “Thoracoscopy—state of the art,” European Respiratory Journal, vol. 11, no. 1, pp. 213–221, 1998. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Y. Wai and P. C. Kuo, “The role of osteopontin in tumor metastasis,” Journal of Surgical Research, vol. 121, no. 2, pp. 228–241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. H. I. Pass, D. Lott, F. Lonardo et al., “Asbestos exposure, pleural mesothelioma, and serum osteopontin levels,” The New England Journal of Medicine, vol. 353, no. 15, pp. 1564–1573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Y. Wai and P. C. Kuo, “Osteopontin: regulation in tumor metastasis,” Cancer and Metastasis Reviews, vol. 27, no. 1, pp. 103–118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. A. Shevde, S. Das, D. W. Clark, and R. S. Samant, “Osteopontin: an effector and an effect of tumor metastasis,” Current Molecular Medicine, vol. 10, no. 1, pp. 71–81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. G. F. Weber, “The cancer biomarker osteopontin: combination with other markers,” Cancer Genomics and Proteomics, vol. 8, no. 6, pp. 263–288, 2011. View at Google Scholar · View at Scopus
  15. S. Van Der Bij, E. Schaake, H. Koffijberg, J. A. Burgers, B. A. J. M. De Mol, and K. G. M. Moons, “Markers for the non-invasive diagnosis of mesothelioma: a systematic review,” British Journal of Cancer, vol. 104, no. 8, pp. 1325–1333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. C. Kao, G. Reid, N. van Zandwijk, D. W. Henderson, and S. Klebe, “Molecular biomarkers in malignant mesothelioma: state of the art,” Pathology, vol. 43, no. 3, pp. 201–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Hollevoet, K. Nackaerts, R. Gosselin et al., “Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma,” Journal of Thoracic Oncology, vol. 6, no. 11, pp. 1930–1937, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. X. Cao, Z. Li, X. Jiang et al., “Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers,” World Journal of Gastroenterology, vol. 18, no. 30, pp. 3923–3930, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. A. N. Husain, T. Colby, N. Ordonez et al., “Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group,” Archives of Pathology and Laboratory Medicine, vol. 137, no. 5, pp. 647–667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. P. G. Chu, D. A. Arber, and L. M. Weiss, “Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms: an immunohistochemical study of 447 cases,” The American Journal of Clinical Pathology, vol. 120, no. 1, pp. 64–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Saqi, S. S. Yun, G. H. Yu et al., “Utility of CD138 (Syndecan-1) in distinguishing carcinomas from mesotheliomas,” Diagnostic Cytopathology, vol. 33, no. 2, pp. 65–70, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. F. P. O'Connell, J. L. Pinkus, and G. S. Pinkus, “CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms,” American Journal of Clinical Pathology, vol. 121, no. 2, pp. 254–263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. C. Rapraeger, B. J. Ell, M. Roy et al., “Vascular endothelial-cadherin stimulates syndecan-1-coupled insulin-like growth factor-1 receptor and cross-talk between αvβ3 integrin and vascular endothelial growth factor receptor 2 at the onset of endothelial cell dissemination during angiogenesis,” FEBS Journal, vol. 280, no. 10, pp. 2194–2206, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. K. J. McQuade and A. C. Rapraeger, “Syndecan-1 transmembrane and extracellular domains have unique and distinct roles in cell spreading,” The Journal of Biological Chemistry, vol. 278, no. 47, pp. 46607–46615, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. D. M. Beauvais, B. J. Ell, A. R. McWhorter, and A. C. Rapraeger, “Syndecan-1 regulates α vβ 3 and α vβ 5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor,” Journal of Experimental Medicine, vol. 206, no. 3, pp. 691–705, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. J. Carey, “Syndecans: multifunctional cell-surface co-receptors,” Biochemical Journal, vol. 327, part 1, pp. 1–16, 1997. View at Google Scholar · View at Scopus
  27. S. Brule, N. Charnaux, A. Sutton et al., “The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9,” Glycobiology, vol. 16, no. 6, pp. 488–501, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Su, S. A. Blaine, D. Qiao, and A. Friedl, “Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation,” Cancer Research, vol. 68, no. 22, pp. 9558–9565, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. R. D. Sanderson, “Heparan sulfate proteoglycans in invasion and metastasis,” Seminars in Cell and Developmental Biology, vol. 12, no. 2, pp. 89–98, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. V. C. Ramani, A. Purushothaman, M. D. Stewart et al., “The heparanase/syndecan-1 axis in cancer: mechanisms and therapies,” FEBS Journal, vol. 280, no. 10, pp. 2294–2306, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Garusi, S. Rossi, and R. Perris, “Antithetic roles of proteoglycans in cancer,” Cellular and Molecular Life Sciences, vol. 69, no. 4, pp. 553–579, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Kumar-Singh, W. Jacobs, K. Dhaene et al., “Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome,” The Journal of Pathology, vol. 186, no. 3, pp. 300–305, 1998. View at Google Scholar
  33. T. L. Nguyen, W. E. Grizzle, K. Zhang, O. Hameed, G. P. Siegal, and S. Wei, “Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer,” American Journal of Clinical Pathology, vol. 140, no. 4, pp. 468–474, 2013. View at Google Scholar
  34. C. Seidel, A. Sundan, M. Hjorth et al., “Serum syndecan-1: a new independent prognostic marker in multiple myeloma,” Blood, vol. 95, no. 2, pp. 388–392, 2000. View at Google Scholar
  35. H. Joensuu, A. Anttonen, M. Eriksson et al., “Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer,” Cancer Research, vol. 62, no. 18, pp. 5210–5217, 2002. View at Google Scholar · View at Scopus
  36. M. Metintas, G. Hillerdal, S. Metintas, and P. Dumortier, “Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors,” Archives of Environmental and Occupational Health, vol. 65, no. 2, pp. 86–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Mundt, G. Nilsonne, S. Arslan et al., “Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma,” PLoS ONE, vol. 8, no. 8, Article ID e72030, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Hirayama, C. Tabata, R. Tabata et al., “Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma,” Respiratory Medicine, vol. 105, no. 1, pp. 137–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. M. J. Pencina, S. D'Agostino, and R. S. Vasan, “Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond,” Statistics in Medicine, vol. 27, no. 2, pp. 157–172, 2008. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  40. E. W. Steyerberg, A. J. Vickers, N. R. Cook et al., “Assessing the performance of prediction models: a framework for traditional and novel measures,” Epidemiology, vol. 21, no. 1, pp. 128–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. W. Hosmer, T. Hosmer, S. Le Cessie, and S. Lemeshow, “A comparison of goodness-of-fit tests for the logistic regression model,” Statistics in Medicine, vol. 16, no. 9, pp. 965–980, 1997. View at Google Scholar
  42. J. Budczies, F. Klauschen, B. V. Sinn et al., “Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization,” PLoS ONE, vol. 7, no. 12, Article ID e51862, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Anttonen, P. Heikkilä, M. Kajanti, M. Jalkanen, and H. Joensuu, “High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery,” Lung Cancer, vol. 32, no. 3, pp. 297–305, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Fujiya, J. Watari, T. Ashida et al., “Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer,” Japanese Journal of Cancer Research, vol. 92, no. 10, pp. 1074–1081, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. A. C. Rapraeger, “Synstatin: A selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis,” FEBS Journal, vol. 280, no. 10, pp. 2207–2215, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. S. C. Dong, J. Kim, H. Ryu et al., “Syndecan-1, a key regulator of cell viability in endometrial cancer,” International Journal of Cancer, vol. 121, no. 4, pp. 741–750, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. H. Teng, R. S. Aquino, and P. W. Park, “Molecular functions of syndecan-1 in disease,” Matrix Biology, vol. 31, no. 1, pp. 3–16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Lovell, J. A. Dunn, G. Begum et al., “Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival,” British Journal of Haematology, vol. 130, no. 4, pp. 542–548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. F. Zong, E. Fthenou, J. Castro et al., “Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains,” Cell Proliferation, vol. 43, no. 1, pp. 29–40, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Grigoriu, B. Chahine, F. Zerimech et al., “Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma,” Clinical Biochemistry, vol. 42, no. 10-11, pp. 1046–1050, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. C. E. Hooper, A. J. Morley, P. Virgo, J. E. Harvey, B. Kahan, and N. A. Maskell, “A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions,” European Respiratory Journal, vol. 41, no. 1, pp. 18–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. M. L. Fitzgerald, Z. Wang, P. W. Park, G. Murphy, and M. Bernfield, “Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase,” Journal of Cell Biology, vol. 148, no. 4, pp. 811–824, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Bernfield, M. Götte, P. W. Park et al., “Functions of cell surface heparan sulfate proteoglycans,” Annual Review of Biochemistry, vol. 68, pp. 729–777, 1999. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Götte, “Syndecans in inflammation,” The FASEB Journal, vol. 17, no. 6, pp. 575–591, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Ding, M. Lopez-Burks, J. A. Sánchez-Duran, M. Korc, and A. D. Lander, “Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells,” Journal of Cell Biology, vol. 171, no. 4, pp. 729–738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Purushothaman, L. Chen, Y. Yang, and R. D. Sanderson, “Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma,” Journal of Biological Chemistry, vol. 283, no. 47, pp. 32628–32636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Oh, J. Kim, H. Ahn et al., “Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor κB,” Gynecologic Oncology, vol. 114, no. 3, pp. 509–515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. C. A. Thompson, A. Purushothaman, V. C. Ramani, I. Vlodavsky, and R. D. Sanderson, “Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes,” Journal of Biological Chemistry, vol. 288, no. 14, pp. 10093–10099, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. V. C. Ramani and R. D. Sanderson, “Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse,” Matrix Biology: Journal of the International Society for Matrix Biology, vol. 35, pp. 215–222, 2013. View at Publisher · View at Google Scholar
  60. A. Anttonen, S. Leppä, T. Ruotsalainen, H. Alfthan, K. Mattson, and H. Joensuu, “Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy,” Lung Cancer, vol. 41, no. 2, pp. 171–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Anttonen, S. Leppä, P. Heikkilä, R. Grenman, and H. Joensuu, “Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations,” Journal of Cancer Research and Clinical Oncology, vol. 132, no. 7, pp. 451–457, 2006. View at Publisher · View at Google Scholar · View at Scopus